These mutations lead to reduced RBM10 expression in LUAD, and this decrease is significantly higher in patients with stage IV LUAD than in those with stage I–III LUAD, suggesting a role for RBM10 in tumor metastasis [18, 19]. Here, RBM10 is linked to neoplasm.